Resources To Help Your Patients With MACI Knee Surgery Cost
Important Safety Information
Full Prescribing Information
Cartilage Repair Blog
Go to Patient Site
Go to Patient Site

Intended for U.S. health care professionals only

My Cartilage Care logo

Dedicated Support Tailored to Your Patients

A dedicated MyCartilageCare Case Manager is committed to offering comprehensive support tailored to your patient’s individual insurance requirements and treatment goals. Call 1-877-872-4643 or email [email protected].

MyCartilageCare offers support including:

Shield Icon

Insurance
support

Dots Icon

Copay
program

Phone Icon

Treatment
education

Chondrocytes Icon

Biopsy
storage

Patient insurance support

MyCartilageCare can provide patient benefit investigation, predetermination & prior authorization, and reimbursement support.

MyCartilageCare.com/healthcare-professionals 
#
#

Assist CoPay Program

MyCartilageCare Assist CoPay Program is a copay assistance program for eligible adult patients who are undergoing surgery with MACI (autologous cultured chondrocytes on porcine collagen membrane) to repair their knee cartilage damage.*

Review Full Terms and Conditions

*The MCC Assist CoPay Program is only valid in the U.S. for eligible patients 18 years or older with commercial/private insurance. The program is not valid for patients enrolled in or covered under any government healthcare insurance programs or where the entire cost of the implant is reimbursed by a plan. The program provides assistance with the out-of-pocket costs for the MACI implant only. The program does not cover the costs of any other healthcare provider charges, including procedure charges, office visit fees, or any other costs. Use of implant must be for an FDA-approved indication. The program is not valid where prohibited by law, taxed, or otherwise restricted. Additional terms and conditions, eligibility requirements, and restrictions apply. See mycartilagecare.com/assist.

Indication and Important Safety Information

Important Safety Information

Contraindications: MACI is contraindicated in patients with a known history of hypersensitivity to gentamicin, other aminoglycosides, products of porcine or bovine origin; in patients with severe osteoarthritis of the knee, inflammatory arthritis, inflammatory joint disease, or uncorrected congenital blood coagulation disorders; in patients who have undergone prior knee surgery in the past 6 months, excluding surgery to procure a biopsy or a concomitant procedure to prepare the knee for a MACI implant; or in patients unable to cooperate with a physician-prescribed post-surgical rehabilitation program.

Warnings and Precautions:
  • Malignancy: The risk of MACI in patients with malignancy in the area of cartilage biopsy or implant is unknown. Expansion of malignant or dysplastic cells present in biopsy tissue during manufacture and subsequent implantation may be possible.
  • Transmissible infectious diseases: Because patients undergoing procedures associated with MACI are not routinely tested for transmissible infectious diseases, cartilage biopsy and MACI implant may carry risk of transmitting infectious diseases.
  • Presurgical Comorbidities: Local inflammation or active infection in the bone, joint, and surrounding soft tissue, meniscal pathology, cruciate ligament instability, and misalignment should be assessed and treated prior to or concurrent with MACI implantation.
  • Product Sterility: Final sterility test results are not available at the time of shipping.

Adverse Reactions: The most frequently occurring adverse reactions reported for MACI (≥5%) were arthralgia, tendonitis, back pain, joint swelling, and joint effusion. Serious adverse reactions reported for MACI were arthralgia, cartilage injury, meniscus injury, treatment failure, and osteoarthritis.

Specific Populations:
  • Use of MACI in pediatric patients (younger than 18 years of age) or in patients over 65 years of age has not been established.
  • The MACI implant is not recommended during pregnancy. For implantations post-pregnancy, the safety of breastfeeding to an infant has not been determined.

To report negative side effects, contact Vericel Corporation at 1-800-453-6948 or FDA at 1-800-FDA-1088 (1-800-332-1088) or www.fda.gov/medwatch.

Please see Full Prescribing Information.

Indication

MACI® is an autologous cellularized scaffold product indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults.

MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults.

Limitations of Use

Effectiveness of MACI in joints other than the knee has not been established.

Safety and effectiveness of MACI in patients over the age of 55 years have not been established.